223 related articles for article (PubMed ID: 10923365)
1. [Probiotics for prevention of ulcerative colitis recurrence: alternative medicine added to standard treatment?].
Folwaczny C
Z Gastroenterol; 2000 Jun; 38(6):547-50. PubMed ID: 10923365
[No Abstract] [Full Text] [Related]
2. [Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine].
Adam B; Liebregts T; Holtmann G
Z Gastroenterol; 2006 Mar; 44(3):267-9. PubMed ID: 16514573
[No Abstract] [Full Text] [Related]
3. Efficacy of a symbiotic product during clinical relapse of ulcerative colitis.
Guslandi M
J Clin Gastroenterol; 2011; 45(5):475-6. PubMed ID: 21336142
[No Abstract] [Full Text] [Related]
4. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
[TBL] [Abstract][Full Text] [Related]
5. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study.
Henker J; Müller S; Laass MW; Schreiner A; Schulze J
Z Gastroenterol; 2008 Sep; 46(9):874-5. PubMed ID: 18810672
[TBL] [Abstract][Full Text] [Related]
6. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
8. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
[TBL] [Abstract][Full Text] [Related]
9. [Probiotics in chronic inflammatory bowel disease].
Böhm S; Kruis W
MMW Fortschr Med; 2006 Aug; 148(35-36):30-4. PubMed ID: 16995360
[TBL] [Abstract][Full Text] [Related]
10. Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad.
Faubion WA; Sandborn WJ
Gastroenterology; 2000 Mar; 118(3):630-1. PubMed ID: 10702217
[No Abstract] [Full Text] [Related]
11. High-dose mesalazine treatment for ulcerative colitis patients who relapse under low-dose maintenance therapy.
Yamamoto T; Umegae S; Matsumoto K
Dig Liver Dis; 2011 May; 43(5):386-90. PubMed ID: 21195041
[TBL] [Abstract][Full Text] [Related]
12. Ulcerative colitis treatment for children and teens.
FDA Consum; 2007; 41(2):5. PubMed ID: 17582854
[No Abstract] [Full Text] [Related]
13. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.
Zocco MA; dal Verme LZ; Cremonini F; Piscaglia AC; Nista EC; Candelli M; Novi M; Rigante D; Cazzato IA; Ojetti V; Armuzzi A; Gasbarrini G; Gasbarrini A
Aliment Pharmacol Ther; 2006 Jun; 23(11):1567-74. PubMed ID: 16696804
[TBL] [Abstract][Full Text] [Related]
14. [Interstitial nephritis associated with mesalazine therapy].
Vuotila M; Ikäheimo R; Pietiläinen T
Duodecim; 2003; 119(20):1978-82. PubMed ID: 14640003
[No Abstract] [Full Text] [Related]
15. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
Hanai H; Iida T; Takeuchi K; Watanabe F; Maruyama Y; Andoh A; Tsujikawa T; Fujiyama Y; Mitsuyama K; Sata M; Yamada M; Iwaoka Y; Kanke K; Hiraishi H; Hirayama K; Arai H; Yoshii S; Uchijima M; Nagata T; Koide Y
Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1502-6. PubMed ID: 17101300
[TBL] [Abstract][Full Text] [Related]
16. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
Moum B
Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043
[TBL] [Abstract][Full Text] [Related]
17. Mesalamine (5-aminosalicylic acid) therapy well tolerated in a patient with aspirin hypersensitivity and ulcerative colitis.
Murphy SJ; Mayer L; Abreu MT
J Clin Gastroenterol; 2011 Jan; 45(1):83-4. PubMed ID: 20535023
[No Abstract] [Full Text] [Related]
18. [Ulcerative colitis].
Felley C; Michetti P
Rev Med Suisse Romande; 2002 Sep; 122(9):441-4. PubMed ID: 12422474
[No Abstract] [Full Text] [Related]
19. Once-daily mesalamine (Lialda) for ulcerative colitis.
Med Lett Drugs Ther; 2007 Mar; 49(1257):25-6. PubMed ID: 17375030
[No Abstract] [Full Text] [Related]
20. [Ulcerative colitis. Complementary therapies].
Matthes H; Moser G; Jantschek G
Z Gastroenterol; 2004 Sep; 42(9):1031-2. PubMed ID: 15455282
[No Abstract] [Full Text] [Related]
[Next] [New Search]
